Drug and Drug-like Molecule Binding to Interface of SARS-CoV-2 Sprotein:human ACE2 Complex: A Density Functional Theory Study
SARS-CoV-2 S-protein:human ACE2 complex models.QM-MM optimized active site model of SARS-CoV-2 S-protein:human ACE2 interface.ONIOM(B3LYP/6-31G*:PM7) method is the chosen QM-MM method. DFT B3LYP/6-31G* level data on energetics is reported for drug-receptor interaction.Several FDA approved drugs and traditional herbal isolates are modelled.Used Gaussian16 to model the systems.The interface cavity of SARS-CoV-2 S-protein:human ACE2 complex (M) for ligand (L) binding is modelled using a two layer ONIOM(B3LYP/6-31G*:PM7) method for sixteen traditional herbal isolates (THI) and nineteen drugs. The binding energy (Eb) of ML complexes increased with increase in dipole moment of Ls. Eb better than -80.0 kcal/mol is observed for digallic acid and adenosine 3',5'-bisphosphate whereas myricetin, glucogallin, sapropterin, tetrahydrobiopterin, protirelin and fidarestat showed Eb better than -60.0 kcal/mol. Multiple noncovalent interactions emanating from arginine, histidine, tyrosine, lysine, carboxylate and amide units (total around 6 - 8) of L, S-protein and ACE2 receptors provide the high binding energy. The sugar substitute aspartame modified with myricetin unit showed the best Eb -91.7 kcal/mol. ONIOM-linked DFT study is effective, affordable and reliable for a quantum chemical rational design approach to model drug-receptor binding process for COVID-19 drug development which sheds light upon the noncovalent binding features of receptor cavity..
Medienart: |
Preprint |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
chemRxiv.org - (2021) vom: 18. Nov. Zur Gesamtaufnahme - year:2021 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Suresh, CH [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
---|
doi: |
10.26434/chemrxiv.13066061 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
XCH019076029 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | XCH019076029 | ||
003 | DE-627 | ||
005 | 20230429143046.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201010s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.26434/chemrxiv.13066061 |2 doi | |
035 | |a (DE-627)XCH019076029 | ||
035 | |a (chemrXiv)10.26434/chemrxiv.13066061 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Suresh, CH |e verfasserin |4 aut | |
245 | 1 | 0 | |a Drug and Drug-like Molecule Binding to Interface of SARS-CoV-2 Sprotein:human ACE2 Complex: A Density Functional Theory Study |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a SARS-CoV-2 S-protein:human ACE2 complex models.QM-MM optimized active site model of SARS-CoV-2 S-protein:human ACE2 interface.ONIOM(B3LYP/6-31G*:PM7) method is the chosen QM-MM method. DFT B3LYP/6-31G* level data on energetics is reported for drug-receptor interaction.Several FDA approved drugs and traditional herbal isolates are modelled.Used Gaussian16 to model the systems.The interface cavity of SARS-CoV-2 S-protein:human ACE2 complex (M) for ligand (L) binding is modelled using a two layer ONIOM(B3LYP/6-31G*:PM7) method for sixteen traditional herbal isolates (THI) and nineteen drugs. The binding energy (Eb) of ML complexes increased with increase in dipole moment of Ls. Eb better than -80.0 kcal/mol is observed for digallic acid and adenosine 3',5'-bisphosphate whereas myricetin, glucogallin, sapropterin, tetrahydrobiopterin, protirelin and fidarestat showed Eb better than -60.0 kcal/mol. Multiple noncovalent interactions emanating from arginine, histidine, tyrosine, lysine, carboxylate and amide units (total around 6 - 8) of L, S-protein and ACE2 receptors provide the high binding energy. The sugar substitute aspartame modified with myricetin unit showed the best Eb -91.7 kcal/mol. ONIOM-linked DFT study is effective, affordable and reliable for a quantum chemical rational design approach to model drug-receptor binding process for COVID-19 drug development which sheds light upon the noncovalent binding features of receptor cavity. | ||
650 | 4 | |a Chemistry |7 (dpeaa)DE-84 | |
650 | 4 | |a 540 |7 (dpeaa)DE-84 | |
773 | 0 | 8 | |i Enthalten in |t chemRxiv.org |g (2021) vom: 18. Nov. |
773 | 1 | 8 | |g year:2021 |g day:18 |g month:11 |
856 | 4 | 0 | |u http://dx.doi.org/10.26434/chemrxiv.13066061 |z kostenfrei |3 Volltext |
912 | |a GBV_XCH | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2021 |b 18 |c 11 |